Additional File 5: Baseline health system costs by disease state 1 Baseline health system costs (except receipt of chemotherapy; see below) were determined using 2 data from the Ministry of Health that through a national unique identifier brings together all 3 hospital, outpatient, pharmaceutical and laboratory events, and some primary care event and 4 private hospital event data (so-called HealthTracker costs). This data has become reliable from about 5
2006. Each event is then assigned a unit cost, making it possible to determine annual, monthly or 6 other costs per person, and type of person (e.g. cancer patient in certain phase of cancer journey). 7
About 80% of all Government Vote Health expenditure can be attributed to separate events by 8 individual New Zealand residents. New Zealand has a capitated funding formula for primary care, so 9 an average cost is assigned to all residents based on their sex, age, ethnicity and deprivation 10 (variables used in the capitation funding formula). Thus the primary care costs are 'expectations' and 11 will (say) underestimate resource use for a cancer patient also seeing their general practitioner more 12 frequently that than the average for someone of the same demographic group. 13
At the time of writing this paper, private or out of pocket health expenditure has not been included 14 in the baseline health system costs. This will result in an underestimate for primary care and private 15 hospital or physician utilisation. However, it should not be too severe for colon cancer costs which 16 are largely public and hospital-based. 17
Costs are calculated separately by sex and age -but not by ethnicity and deprivation. There are two 18 reasons for this decision. First, due to different usage of private health care (and out of pocket) by 19 ethnicity and deprivation, any differences by ethnicity and deprivation in costs observed with 20
HealthTracker are likely to be (in part at least) of these unobserved differences at the margin. 21
Second, it is a moot point whether current differences in health service utilisations by ethnicity and 22 deprivation are appropriate or fair. 23
The remainder of this file is in three sections:  Population health system costs. That is health system costs of an average New Zealander by 25 sex and age, regardless of disease status. We use these costs for two purposes: for health 26 system costs beyond the eight year cure time for colon cancer (i.e. unrelated future health 27 system costs); to assist calculating excess health system costs due to colon cancer. 28  Excess colon cancer health system costs. 29  Costs of receipt of chemotherapy. 30
Population health system costs 31
Two datasets were created: one for costs and person time occurring not in the last six months of life, 32 and one for its complement of costs and person time in the last six months of life. This follows the 33 recommendations of van Baal to specify costs near the end of life separately[1] , and as described in 34 the BODE 3 protocol [2] . For each dataset, averaged health system costs per person-month for the 35 whole population were calculated for all cross-classified strata of sex by age (5-year age-groups) by 36 ethnicity (Māori, non-Māori) by deprivation (three categories) by calendar year (2007, 08, 09, 10, 37 11). Gamma regression was then used to generate smoothed estimates of health system costs. For 38 reasons explained above, ethnicity and deprivation were not included as covariates in this model, 39 although the input data was disaggregated by these strata. Each age group was assigned its mid-40 point age in years, minus 62.5 so as to centre age on the 60-64 year age group. The dependent 41 variable itself was the logarithm of average cost per person-month in each strata. As the input data 42 to the regressions was grouped, the regressions were weighted by the total number of people 43 contributing person-time. The estimated costs per person month are shown in Table 1 below, and 44 the regression coefficients given in footnotes. 45 
54
Colon cancer stage III health system costs 55 The HealthTracker data was restricted to people diagnosed with SEER regional extent of disease 56 stage colon cancer -a reasonable match with stage III. Within each stratum, the observed average cost per month was calculated (top panel, Table 2 ). Then 68 the 'excess cost' was calculated by subtracting the matching population costs for the population 'not 69 in the last six months of life' (Table 1 above Table  76 2, and the regression equation coefficients and standard errors are shown in Table 3 . 77 Chemotherapy costs 86 It was not possible to accurately identify, and determine baseline costs, for people receiving 87 chemotherapy from HealthTracker. Therefore, we undertook a bottom-up costing of chemotherapy 88 as follows: cost of chemotherapy itself; cost of staff time and out-patient's attendances. We chose 89 the FOLFOX4 chemotherapy regimen (see Box 1) [3] as: 90  this is a commonly prescribed regimen in New Zealand for colon cancer patients stage III 91 along with other FOLFOX regimens. 92  it is recommend by New Zealand Guidelines Group [4] 93  it concords with the treatment regimen from in the literature used for intervention input 94 parameters as described in Table 1 of the main paper. 95
We calculated the costs for the FOLFOX4 regimen for the total six month cost and per cycle. Each 96 cycle lasts two days and is every two weeks so there are 12 cycles overall. The acquisition cost of the 97 drugs was sought from the Pharmaceutical Schedule August 2011. The outpatient chemotherapy 7 outpatient oncology appointments with an oncologist was provided by a local key informant 100 (consultant oncologist) as 6-12 (every 2-4 weeks ;patients are usually seen by an oncologist at the 101 start of every cycle but there is a moving trend to seeing patients every other cycle). We chose to 102 cost six outpatient appointments with an oncologist assuming that each appointment at the start of 103 each new cycle would be shorter in length than an average oncology appointment costed by the 104 National Pricing Outpatient Purchase Unit for DHBs (2011). 105
We then recalculated the DT costs for months 4 to 9 (inclusive) such that the average was 106 maintained (using the baseline proportion of people receiving chemotherapy), but costs for those 107 people receiving chemotherapy were $17811.78 greater (per patient) than those not receiving 108
chemotherapy. 109
We did not include knock on costs of complications secondary to chemotherapy as the incidence of 110 these is low. The incidence of febrile neutropenia with FOLFOX4 is 1.8%, the incidence of 111 gastrointestinal adverse effects is low and the incidence of grade 3 sensory neuropathy was 12.4 % 112 during treatment, decreasing to 1.1 % at one year of follow-up [3] . In addition, there is minimal 113 treatment available for sensory neuropathy which gave us further reason not to cost it. 114 *IV fluids given with the chemo agent (e.g. 5% glucose) are not costed separately as they are included in the outpatient chemotherapy per attendance cost. 117 **We have rounded up the dose of each chemotherapy agent to the nearest vial size as suggested by Dooley et al whose work showed by doing this had minimal impact on 118 the cost of chemotherapy agents. [5] .
Box 1: Chemotherapy treatment outline FOLFOX4

